Public Tenders and B-BBEE Requirements for SAHPRA Licence Holders in South Africa
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
In South Africa, the establishment licence is not only the precondition of lawful operation but also a gate to commercial access. SAHPRA states officially that proof of a valid SAHPRA medical device establishment licence must be provided to qualify for National and Provincial tenders. In addition, participation in government procurement generally involves Broad-Based Black Economic Empowerment (B-BBEE) scoring requirements. For companies targeting the public healthcare system, the time value of the establishment licence far exceeds its cost.
2. Legal basis
| Instrument | Reference / Number | Publication date | Provision |
|---|---|---|---|
| SAHPRA medical devices page | Published on the SAHPRA official website | Current version, verified as at 29 October 2026 | Licensing of Medical Device Establishments section, Note 1 (participation in National and Provincial tenders requires proof of a valid establishment licence) |
| Medicines and Related Substances Act | Act No. 101 of 1965 | Enacted and published in 1965, subsequently amended; verified as at 29 October 2026 | Section 22C(1)(b) (mandatory nature of licensing) |
| Regulations relating to Medical Devices and In Vitro Diagnostic Medical Devices (IVDs) | Government Gazette No. 40480, Notice No. 1515 | Published on 9 December 2016 | Regulation 2 (manner and conditions for allowing international tendering); Regulation 5 (licensing) |
| Broad-Based Black Economic Empowerment framework | B-BBEE legislation and implementation codes | Current version, verified as at 29 October 2026 | B-BBEE scoring requirements in government procurement |
3. Expert insights
Insight 1: Note 1 elevates the licence from a compliance document to a tender qualification. The official SAHPRA note reads that proof of a valid establishment licence must be provided in order to qualify for tenders. This means the consequence of holding no licence goes beyond administrative penalties: it is the direct loss of the public procurement market. For categories dominated by the public system, such as consumables, basic diagnostics and imaging equipment, this single requirement is decisive for market-entry planning. In tender documents, the licence number and premises details are routinely checked against the SAHPRA register, so any mismatch delays qualification.
Insight 2: Regulation 2 specifically governs international tendering, showing that cross-border procurement has its own rules. In the structure of the 2016 regulations, Regulation 2 covers the manner and conditions for allowing international tendering. This provides a channel for foreign entities to participate in South African procurement, but the conditions must be confirmed against that provision and the individual tender notice rather than assumed, because each procurement authority applies them within its own documentation. Foreign suppliers should read tender notices with this provision in mind, since the conditions determine whether a direct bid or a local partnership is the workable route.
Insight 3: B-BBEE is a commercial access variable unique to South Africa. B-BBEE scoring affects competitiveness in government procurement awards. Practical estimate: foreign-invested companies typically improve their scoring through local partnerships, local shareholding structures, skills transfer and local procurement; the specific approach must be designed case by case against the company’s structure, and consulting South African local professional advisers is strongly recommended before commitments are made. B-BBEE planning should also start well before the first tender deadline, because structural changes take longer to implement than licence applications.
Insight 4: Class A exempt establishments are excluded from public procurement. Non-sterile, non-measuring Class A devices are exempt from the establishment licence, yet tenders require a valid licence, not merely a demonstration that a licence is legally required. This means exempt establishments must proactively apply for a licence if they wish to enter the public market — a classic case of an obligation that is not legally mandatory but commercially unavoidable. The commercial logic is straightforward: the exemption saves the licence fee but forecloses the largest buyer in the market.
Insight 5: Licence validity must be maintained throughout the tender period. Tendering, evaluation and contract performance can span multiple years, and the payment status of the annual retention fee directly affects licence validity. A single missed retention fee leading to cancellation could push a contract already under performance into breach, so payment discipline is part of contract risk management, not merely a regulatory chore. Diarising the June payment and verifying licence status before each tender submission closes this exposure.
4. Practical recommendations
- Obtain the establishment licence early if targeting the public market: the licence is the tender qualification.
- Class A exempt establishments should apply for a licence proactively: avoid exclusion from tenders.
- Plan the B-BBEE scoring approach early: combining local partners and structural design.
- Confirm international tendering conditions under Regulation 2 and the tender notice.
- Ensure licence validity throughout the tender and performance period: pay retention fees on time.
- Keep licence information in tender documents consistent with SAHPRA records.
5. Verification checklist
- □ Confirmed whether the target market involves National and Provincial tenders
- □ Valid SAHPRA establishment licence obtained (hard qualification for tendering)
- □ Necessity of proactive licence application assessed for Class A exempt establishments
- □ Applicable conditions for international tendering confirmed under Regulation 2
- □ B-BBEE scoring approach planned in advance (practical estimate)
- □ Licence validity covers the full tender and performance cycle
- □ Annual retention fee payment status included in pre-tender checks
- □ Licence information in tender documents consistent with SAHPRA records
Regulatory information verified as at 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the content published by the official sources listed under Legal basis as at that date; where official documents have been updated, the latest published version prevails.
- South Africa local resource: GRZAN can assist manufacturers from the Chinese mainland and overseas in engaging the South African Health Products Regulatory Authority (SAHPRA) on medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification route planning and CAB selection, GMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and adverse event reporting mechanisms.
- Service capabilities: product attribute determination and risk classification (Class A/B/C/D), establishment licence application and renewal, reliance pathway justification, technical documentation and essential principles conformity argumentation, labelling and instructions-for-use localisation in English, and post-market vigilance and annual compliance information submission support.
- Contact: hito.lin@grzan.cn; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us